Potential use of biological proteins for liver failure therapy

Kazuaki Taguchi, Keishi Yamasaki, Hakaru Seo, Masaki Otagiri

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Biological proteins have unlimited potential for use as pharmaceutical products due to their various biological activities, which include non-toxicity, biocompatibility, and biodegradability. Recent scientific advances allow for the development of novel innovative protein-based products that draw on the quality of their innate biological activities. Some of them hold promising potential for novel therapeutic agents/devices for addressing hepatic diseases such as hepatitis, fibrosis, and hepatocarcinomas. This review attempts to provide an overview of the development of protein-based products that take advantage of their biological activity for medication, and discusses possibilities for the therapeutic potential of protein-based products produced through different approaches to specifically target the liver (or hepatic cells: hepatocytes, hepatic stellate cells, liver sinusoidal endothelial cells, and Kupffer cells) in the treatment of hepatic diseases.

Original languageEnglish
Pages (from-to)255-274
Number of pages20
JournalPharmaceutics
Volume7
Issue number3
DOIs
Publication statusPublished - 2015 Aug 31
Externally publishedYes

Fingerprint

Liver Failure
Liver
Hepatocytes
Proteins
Hepatic Stellate Cells
Kupffer Cells
Therapeutics
Hepatitis
Fibrosis
Endothelial Cells
Equipment and Supplies
Pharmaceutical Preparations

Keywords

  • Albumin
  • Drug delivery
  • Erythropoietin
  • Gelatin
  • Hemoglobin
  • Lactoferrin
  • Nanomedicine
  • α-acid glycoprotein

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Potential use of biological proteins for liver failure therapy. / Taguchi, Kazuaki; Yamasaki, Keishi; Seo, Hakaru; Otagiri, Masaki.

In: Pharmaceutics, Vol. 7, No. 3, 31.08.2015, p. 255-274.

Research output: Contribution to journalReview article

Taguchi, Kazuaki ; Yamasaki, Keishi ; Seo, Hakaru ; Otagiri, Masaki. / Potential use of biological proteins for liver failure therapy. In: Pharmaceutics. 2015 ; Vol. 7, No. 3. pp. 255-274.
@article{6054fecd346a4559ba30a50d53331515,
title = "Potential use of biological proteins for liver failure therapy",
abstract = "Biological proteins have unlimited potential for use as pharmaceutical products due to their various biological activities, which include non-toxicity, biocompatibility, and biodegradability. Recent scientific advances allow for the development of novel innovative protein-based products that draw on the quality of their innate biological activities. Some of them hold promising potential for novel therapeutic agents/devices for addressing hepatic diseases such as hepatitis, fibrosis, and hepatocarcinomas. This review attempts to provide an overview of the development of protein-based products that take advantage of their biological activity for medication, and discusses possibilities for the therapeutic potential of protein-based products produced through different approaches to specifically target the liver (or hepatic cells: hepatocytes, hepatic stellate cells, liver sinusoidal endothelial cells, and Kupffer cells) in the treatment of hepatic diseases.",
keywords = "Albumin, Drug delivery, Erythropoietin, Gelatin, Hemoglobin, Lactoferrin, Nanomedicine, α-acid glycoprotein",
author = "Kazuaki Taguchi and Keishi Yamasaki and Hakaru Seo and Masaki Otagiri",
year = "2015",
month = "8",
day = "31",
doi = "10.3390/pharmaceutics7030255",
language = "English",
volume = "7",
pages = "255--274",
journal = "Pharmaceutics",
issn = "1999-4923",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "3",

}

TY - JOUR

T1 - Potential use of biological proteins for liver failure therapy

AU - Taguchi, Kazuaki

AU - Yamasaki, Keishi

AU - Seo, Hakaru

AU - Otagiri, Masaki

PY - 2015/8/31

Y1 - 2015/8/31

N2 - Biological proteins have unlimited potential for use as pharmaceutical products due to their various biological activities, which include non-toxicity, biocompatibility, and biodegradability. Recent scientific advances allow for the development of novel innovative protein-based products that draw on the quality of their innate biological activities. Some of them hold promising potential for novel therapeutic agents/devices for addressing hepatic diseases such as hepatitis, fibrosis, and hepatocarcinomas. This review attempts to provide an overview of the development of protein-based products that take advantage of their biological activity for medication, and discusses possibilities for the therapeutic potential of protein-based products produced through different approaches to specifically target the liver (or hepatic cells: hepatocytes, hepatic stellate cells, liver sinusoidal endothelial cells, and Kupffer cells) in the treatment of hepatic diseases.

AB - Biological proteins have unlimited potential for use as pharmaceutical products due to their various biological activities, which include non-toxicity, biocompatibility, and biodegradability. Recent scientific advances allow for the development of novel innovative protein-based products that draw on the quality of their innate biological activities. Some of them hold promising potential for novel therapeutic agents/devices for addressing hepatic diseases such as hepatitis, fibrosis, and hepatocarcinomas. This review attempts to provide an overview of the development of protein-based products that take advantage of their biological activity for medication, and discusses possibilities for the therapeutic potential of protein-based products produced through different approaches to specifically target the liver (or hepatic cells: hepatocytes, hepatic stellate cells, liver sinusoidal endothelial cells, and Kupffer cells) in the treatment of hepatic diseases.

KW - Albumin

KW - Drug delivery

KW - Erythropoietin

KW - Gelatin

KW - Hemoglobin

KW - Lactoferrin

KW - Nanomedicine

KW - α-acid glycoprotein

UR - http://www.scopus.com/inward/record.url?scp=84940748886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940748886&partnerID=8YFLogxK

U2 - 10.3390/pharmaceutics7030255

DO - 10.3390/pharmaceutics7030255

M3 - Review article

AN - SCOPUS:84940748886

VL - 7

SP - 255

EP - 274

JO - Pharmaceutics

JF - Pharmaceutics

SN - 1999-4923

IS - 3

ER -